Data from large cardiovascular outcomes trials have suggested a potential benefit of treatment with SGLT2 inhibitors on renal outcomes, but these trials generally enrolled patients with relatively healthy kidney function and accrued few hard renal outcomes.[44–46] Ongoing studies with other SGLT2 inhibitors to evaluate potential benefits on chronic kidney disease in patients with and without type 2 diabetes will be needed to confirm whether these results represent a class effect [47, 48], and further analyses would be needed to forecast the long-term effects on progression of DKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.